Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non–muscle-invasive Bladder Cancer

D’Andrea, David; Moschini, Marco; Gust, Kilian M.; Abufaraj, Mohammad; Özsoy, Mehmet; Mathiéu, Romain; Soria, Francesco; Briganti, Alberto; Rouprêt, Morgan; Karakiewicz, Pierre I.

doi:10.1016/j.clgc.2017.03.007

Cited by 36 publications

(26 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, 139 remaining studies were further evaluated for eligibility, and 118 studies were further excluded because they were animal studies, had no survival data with the pretreatment NLR, were without sufficient data to extract the HRs and 95% confidence intervals (CIs), used a continuous variable as the cut-off value, or had overlapping patients or < 10 patients. A total of 21 studies were finally included in this pooled analysis, of which 17 studies included 11, 262 bladder cancer patients treated with RC or TURBT [15-17, 28-41] and 4 studies involved 862 mUC or uUC patients treated with systemic chemotherapy [42-45]. The flow diagram for the study selection process is depicted in Fig.…”

Section: Resultsmentioning

confidence: 99%

Pretreatment Neutrophil-Lymphocyte Ratio as a Predictor in Bladder Cancer and Metastatic or Unresectable Urothelial Carcinoma Patients: a Pooled Analysis of Comparative Studies

Zhao

Wang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Emerging studies have shown that the neutrophil-lymphocyte ratio (NLR) is a potential predictor in various tumors. Our study was conducted to assess the prognostic value of the pretreatment NLR in bladder cancer and metastatic or unresectable urothelial carcinoma (mUC or uUC) patients up to July 2017. The correlation between the pretreatment NLR and pathological characteristics was also evaluated in bladder cancer patients. Methods: The hazard ratio (HR) and odds ratio (OR) with the 95% confidence interval (CI) were extracted or calculated from the included studies for further pooled analysis. A total of 21 studies were included in a pooled analysis. Results: The pooled results indicated that a high pretreatment NLR was associated with reduced overall survival (OS) (HR=1.27, 95% CI=1.12-1.43), relapse-free survival (RFS) (HR=1.41, 95% CI=1.23-1.60), progression-free survival (PFS) (HR=1.75, 95% CI=1.36-2.15), disease-specific survival (DSS) and cancer-specific survival (CSS) (HR=1.27, 95% CI=1.19-1.35) in the bladder cancer patients. Additionally, an elevated pretreatment NLR suggested a worse OS rate in the mUC or uUC patients (HR=1.63, 95% CI=1.34-1.91). The pooled ORs and 95% CIs showed that a high pretreatment NLR could be a risk indicator for certain pathological features, such as lymphovascular invasion, a positive margin status and advanced tumor stage. Conclusions: our results showed that a high pretreatment NLR predicted poor prognosis in bladder cancer, mUC and uUC patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Pretreatment Neutrophil-Lymphocyte Ratio as a Predictor in Bladder Cancer and Metastatic or Unresectable Urothelial Carcinoma Patients: a Pooled Analysis of Comparative Studies

Zhao

Wang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Several papers have reported on the prognostic role of NLR in NMIBC (Table 2) (19,(37)(38)(39)(40)(41)(42)(43)(44)(45)(46). Most of these studies have reported on the relationship between NLR, RFS, and PFS before transurethral resection of bladder tumor (TURBT) (19,(37)(38)(39)(40)(41)(42)(43)(44)(45). Vartolomei et al and Mbeutcha et al analyzed NLR in more than 1,000 patients (19,43).…”

Section: Neutrophil-to-lymphocyte Ratiomentioning

confidence: 99%

“…Several studies have reported on the prognostic role of NLR in MIBC and metastatic BC ( Table 2) (24,41,(47)(48)(49)(50)(51)(52)(53)(54)(55)(56)(57)(58)(59)(60). Furthermore, several studies have reported on the role of prognostic factors in survival outcomes of MIBC and metastatic UC (24, 41, 47, 48, 50, 52-56, 59, 60), while other studies have suggested that the postoperative stages or disease severity can be predicted (Table 3) (41,48,49,58,(69)(70)(71)(72)(73). The majority of the studies reported a positive role of a high NLR on the prediction of worse OS and CSS rates.…”

Section: Neutrophil-to-lymphocyte Ratiomentioning

confidence: 99%

“…The majority of the studies reported a positive role of a high NLR on the prediction of worse OS and CSS rates. Furthermore, elevated NLR has been reported as an independent predictor of recurrence in several studies (32,41,50,52,55), with some reporting higher NLR values in patients with MIBC compared to those with NMIBC (69,70). Other studies have reported on considering the NLR in predicting disease severity, such as extravesical involvement, upstaging, or LN involvement (48,49,55).…”

Section: Neutrophil-to-lymphocyte Ratiomentioning

confidence: 99%

See 1 more Smart Citation

Role of Systemic Inflammatory Response Markers in Urothelial Carcinoma

Yuk

2020

Front. Oncol.

View full text Add to dashboard Cite

Urothelial carcinoma (UC) can occur in various parts of the urinary tract and occurs in different stages and grades. The disease recurs frequently and is monitored through a series of invasive tests, such as cystoscopy or ureteroscopy, over the lifetime of an individual. Although many researchers have attempted to stratify the risks of UC, with the majority being based on cancer characteristics and host factors such as performance status, a risk classification system has yet to be fully developed. Cancer affects various parts of the body through the systemic immune response, including changes in hormones, the number and ratio of white blood cells and platelets, and C-reactive protein (CRP) or albumin levels under the influence of neuroendocrine metabolism, hematopoietic function, and protein and energy metabolism, respectively. Herein, we reviewed various systemic inflammatory response markers (SIRs) related to UC, including CRP, albumin-globulin ratio, albumin, Glasgow prognostic score (GPS), modified GPS, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio. Our aim was to summarize the role of various SIRs in the treatment of patients with UC.

show abstract

“…A summary of 24 recent studies investigating the prognostic role of NLR in RCC according to treatment type is shown in Tables 8–11 . Table summarizes studies investigating the prognostic role of preoperative NLR in patients who underwent transurethral resection for NMIBC.…”

Section: Differential Blood Cell Markersmentioning

confidence: 99%

Role of systemic inflammatory response markers in urological malignancy

Ohno

2018

Int J of Urology

View full text Add to dashboard Cite

The systemic inflammatory response is associated with survival in patients with a variety of cancers. This inflammatory response is measured in the peripheral blood, and can be monitored using two categories of indices: concentration of specific serum proteins (albumin, C‐reactive protein) and differential blood cell count (neutrophils, lymphocytes and platelets). Furthermore, combinations of these indices, such as the Glasgow Prognostic Score, which consists of the serum C‐reactive protein and albumin level; the neutrophil‐to‐lymphocyte ratio; the platelet‐to‐lymphocyte ratio; and the prognostic nutritional index, which is based on peripheral blood lymphocyte count and serum albumin level, have also been evaluated and compared in cancer research. To date, there are hundreds of studies that have shown the prognostic value of systemic inflammatory response markers in patients with urological cancer. Most studies have evaluated the prognostic and predictive role of the pretreatment value of the markers, although some have focused on the role of the post‐treatment value at specific points during the clinical course. The advantages of systemic inflammatory response markers are that they are easily measurable and inexpensive in the clinical setting. However, it is important to consider how clinicians use these markers in clinical practice. The present review provides a concise overview regarding systemic inflammatory markers in urological cancers, specifically C‐reactive protein, Glasgow Prognostic Score/modified Glasgow Prognostic Score, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio and prognostic nutritional index.

show abstract

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non–muscle-invasive Bladder Cancer

Cited by 36 publications

References 23 publications

Pretreatment Neutrophil-Lymphocyte Ratio as a Predictor in Bladder Cancer and Metastatic or Unresectable Urothelial Carcinoma Patients: a Pooled Analysis of Comparative Studies

Pretreatment Neutrophil-Lymphocyte Ratio as a Predictor in Bladder Cancer and Metastatic or Unresectable Urothelial Carcinoma Patients: a Pooled Analysis of Comparative Studies

Role of Systemic Inflammatory Response Markers in Urothelial Carcinoma

Role of systemic inflammatory response markers in urological malignancy

Contact Info

Product

Resources

About